1 – 10 of 13
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Structure and ion-release mechanism of P IB-4-type ATPases
2022) In eLife(
- Contribution to journal › Article
- 2019
-
Mark
Synaptic vesicle protein 2A as a potential biomarker in synaptopathies
(
- Contribution to journal › Scientific review
- 2016
-
Mark
Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis : Observational Data from Southern Sweden
(
- Contribution to journal › Article
-
Mark
Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis : Results of a Randomized Swedish Trial
(
- Contribution to journal › Article
- 2015
-
Mark
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
(
- Contribution to journal › Article
-
Mark
Does disease activity at start of biologic therapy influence work-loss in RA patients?
2015) In Rheumatology (Oxford, England)(
- Contribution to journal › Article
-
Mark
The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study.
(
- Contribution to journal › Article
- 2014
-
Mark
Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
(
- Contribution to journal › Article
-
Mark
Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis inception cohort.
(
- Contribution to journal › Article
- 2013
-
Mark
Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis A Randomized Trial
(
- Contribution to journal › Article